|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
NCCN Guidelines Update on Selection of PSMA PET Imaging Agent in Patient Selection for Lutetium-177–PSMA-617
|
A. Oliver Sartor, MD
Oliver Sartor discusses the updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer and how we can think about selecting patients for treatment with Lutetium-177–PSMA-617 using PSMA PET scans.
|
|
|
|
|
|
|
|
|
|
|
| The Next Wave of Novel Radiopharmaceuticals |
| Shahneen Sandhu, MD, Ph.D., MBBS, FRACP |
| Alicia Morgans is joined by Shahneen Sandhu to discuss targeting prostate-specific membrane antigen (PSMA), specifically lutetium, and the next wave of novel radiopharmaceuticals. |
|
|
|
|
|
|
|
|
|
|
|
|
PSMA PET Imaging Hot Topics
|
Neal Shore, MD, FACS, and Jason Efstathiou, MD
Neal Shore and Jason Efstathiou join Alicia Morgans to discuss the current landscape in PSMA PET imaging. Drs. Shore and Efstathiou share their thoughts on the agents they are using and the impacts of these new developments in imaging, staging and prognostication.
|
|
|
|
|
|
|
|
|
|
|
| Appropriate Use Criteria for PSMA PET Imaging |
| Hossein Jadvar, MD, Ph.D., MPH, MBA, FACNM, FSNMMI |
| Phillip Koo is joined by Hossein Jadvar to discuss the Appropriate Use Criteria (AUC) for PSMA PET in prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
| How To Follow Up Patients Who Had PSMA PET As Baseline Imaging
|
| Tomasz M. Beer, MD, FACP
|
| Tomasz Beer discusses the question of how to follow patients whom PSMA-PET imaging has been used for baseline staging or diagnostic imaging. Dr. Beer emphasized that there are many outstanding questions regarding the use of PSMA-PET/CT response criteria, some of which have been addressed in a recent consensus statement.
|
|
|
|
|
|
|
|
|
|
|
| Treatment of Local Regional Disease in the Era of PSMA PET
|
| Leslie K. Ballas, MD
|
| Leslie Ballas discusses the treatment of local regional disease in the era of PSMA PET. Dr. Ballas notes that the core of the issue is accurate assessment of the extent of disease being essential for guiding treatment decisions.
|
|
|
|
|
|
| Theranostics: The VISION Trial and Beyond
|
| Scott T. Tagawa, MD, MS, FACP
|
| At the Annual Meeting of the Society of Urologic Oncology, there was a session focused on prostate specific membrane antigen (PSMA) and prostate cancer. In the context of this session, Dr. Scott Tagawa presented on the evolving role of prostate cancer theranostics, including not just the VISION trial but subsequent data.
|
|
|
|
|
|
| Progress and Promise in Treatment Personalization for Advanced Prostate Cancer - Lighting the Way: Lutetium in the Treatment Paradigm
|
| Mike Sathekge, MBChB, MMed (Nucl Med), Ph.D.
|
| Mike Sathekge summarizes the potential applications of lutetium in prostate cancer. Imaging is helpful for multiple reasons in prostate cancer, including helping with staging, detection of recurrence, prognostication, response monitoring, and may be helpful in therapeutic strategies and characterizing the heterogeneity of the disease. |
|
|
|
|
|
|
|
|
|
|
|
